30 ans d'énergie saine pour toutes les peaux
Continuer à concevoir l'avenir de la médecine esthétique
(1996-2005)
The Science Comes First
The laser industry had a skin tone problem.
We spent nearly a decade solving it - engineering 650-micropulse pulse technology that made safe treatments across all Fitzpatrick skin types possible for the first time.
We chose to be right, not first.
• 1996
Aerolase founded with a singular misson: create laser technology safe for all skin types.
• 2000
First FDA clearance.
• 2004
Expanded FDA clearances across multiple indications.
• 2005
LightPod Neo & LightPod Era platforms established.
Nine years. Zero shortcuts. The science was proven before commercial pressure ever entered the equation.
We expanded geographically before we expanded commercially.Validation mondiale grâce à l'excellence clinique.
• 2006–2011
U.S. dermatology market entry with clinical research and proof of concept.
• 2012–2015
Additional FDA clearances for Neo; Medical Advisory Board formed; peer-reviewed publications.
Every adoption was intentional. Every case study was a proof point.Nous laissons les résultats cliniques, et non les budgets marketing, favoriser l'adoption. La technologie a fait ses preuves dans les conditions les plus exigeantes.
Nous nous sommes développés géographiquement avant de nous développer commercialement, ce qui nous a permis d'adopter les KOL et de créer des études de cas auprès de diverses populations de patients dans le monde entier.
(2006 à 2015)
Prouver que cela fonctionne partout
We didn't chase volume — we chose our first customers as carefully as we'd chosen our technology. Clinical outcomes, not marketing budgets, drove adoption.
(2016-2021)
From Clinic to the World Stage
With clinical validation in hand, we expanded internationally and launched the next generation of laser platforms.
From proof of concept to product launch.
• 2016–2017
International expansion into Europe, the Middle East, Asia and Africa.
• 2018
Neo Elite, Era Elite and Neo V launched.
• 2019–2021
North America commerical infrastructure built out.
From Technology pioneer to market leader.
• 2022
Major sales expansion across North America , Exci308 added to the Aerolase technology portfolio, business plan to target Dermatologists, Plastic Surgeons, and Aestheticians.
• 2023
Australia market development, expanded KOL network across all specialties.
• 2024
Matured sales infrastructure and market segmentation, formalized customer success programs.
• 2025
Hybrid Fractional Era launched, Aerolase India established, Era Focus in development.
(2022-2025)
Building the Engine to Scale
The science was undeniable — now we built the commercial engine to match it.
(2026+)
The Confidence Era
Proving what 30 years of precision enables.
Three decades of physics-first innovation. One unwavering commitment: healthy energy that works for every patient, every time.
The Next 30 Years
We're not just celebrating where we've been. We're defining where the industry is going!
Trois décennies d'impact
Plus de 3 000
Pratiques servies.
1 M
Patients traités.
Plus de 25 ans
Pays atteints.
I-VI
Types de peau traités en toute sécurité.
30 Years, In Their Words
« Depuis longtemps, nous recherchions des appareils sûrs et efficaces pour une variété de tons de peau. Pour les patients à la peau plus foncée qui recherchent une épilation, un rajeunissement, un traitement des vaisseaux sanguins, des ecchymoses, nous n'avions pas vraiment cet appareil avant l'arrivée de l'Aerolase. Il est sûr et efficace et je peux l'utiliser sur n'importe quel patient. »
